According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “
ZEAL has been the subject of a number of other research reports. Needham & Company LLC started coverage on ZEALAND PHARMA/S in a research report on Thursday, May 14th. They set a “buy” rating and a $42.00 target price for the company. ValuEngine raised ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Thursday, March 5th. Finally, Morgan Stanley raised their target price on shares of ZEALAND PHARMA/S from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. ZEALAND PHARMA/S currently has an average rating of “Hold” and an average target price of $40.25.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($4.98) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($4.35). ZEALAND PHARMA/S had a negative return on equity of 51.41% and a negative net margin of 1,157.20%. The company had revenue of $1.83 million during the quarter, compared to the consensus estimate of $5.13 million. On average, research analysts anticipate that ZEALAND PHARMA/S will post -3.07 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in ZEAL. UBS Group AG acquired a new position in ZEALAND PHARMA/S during the first quarter valued at approximately $40,000. Jane Street Group LLC boosted its position in shares of ZEALAND PHARMA/S by 14.2% during the fourth quarter. Jane Street Group LLC now owns 13,634 shares of the company’s stock worth $482,000 after purchasing an additional 1,692 shares in the last quarter. Morgan Stanley grew its holdings in shares of ZEALAND PHARMA/S by 4.6% in the 1st quarter. Morgan Stanley now owns 14,272 shares of the company’s stock valued at $493,000 after buying an additional 631 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of ZEALAND PHARMA/S by 163.9% in the 4th quarter. Renaissance Technologies LLC now owns 27,978 shares of the company’s stock valued at $929,000 after buying an additional 17,378 shares in the last quarter. 6.38% of the stock is currently owned by hedge funds and other institutional investors.
ZEALAND PHARMA/S Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
See Also: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.